KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Trial details
- Registry ID
- NCT06193889
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisNCT06193889 | Kyverna Therapeutics | Phase 2, Phase 3 | Recruiting | 2027-09Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |